A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines. by Rajkumar, T. & Gullick, W. J.
Br. J. Cancer (1994), 76, 459-465
C) Maanlllan
A monoclonal antibody to the human c-erbB3 protein stimulates the
anchorage-independent growth of breast cancer cell lines
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S_ hy Te c-erbB3 protein is a member of the type I growth factor receptor family. It has a widespread
pattern of expression in normal tissus and is overexpressed in about 20% of breast cancers. We have raised a
specific monockoal antibody, caled SGP1, against the extracellular domain of c-erbB3 which recognises the
native form of the protein The monockoal antibody was found to modestly but signifcntly stimulate the
anchorage-idependent doning efficincy of the breast tumour cell lines BT483 and T47D, both of which
express the c-erbB3 protein. No effect was observed on 293 cells lacing expresson, nor did a control
isotype-matched antibody promote the growth of any of the cells tested. These results suggest that the c-erbB3
protein may normaRy act as a growth factor receptor.
Monoclonal antibodies are useful tools to study the function
of growth factor receptors for which there is no known
ligand. These may act either as agonists or as antagonists
and thus give an insight into the physiological function ofthe
receptor. Monoclonal antibodies have been raised in the past
against the extracellular domain of both the epidermal
growth factor receptor (EGFR) and c-erbB2 receptors which
have been used to gain a greater understanding of the func-
tion of these proteins (Fernandez-Pol, 1985; Harwerth et al.,
1993). In addition, such reagents have potential value as
vectors for novel therapeutic agents (Meyer et al., 1993; Trail
et al., 1993).
c-erbB3 belongs to the type I growth factor receptor
family, whose other members include the EGFR, c-erbB2
and c-erbB4 proteins. Ligands have been identified for the
EGFR (EGF, transforming growth factor alpha, amphi-
regulin, heparin-binding EGF and betaceluin) (Prigent &
Lemoine, 1992) and c-erbB4 [heregulin/neu differentiation
factor (NGF)] (Plowman et al., 1993a). Very recently it has
been shown that NDF/heregulin also binds to and stimulates
the kinase activity of c-erbB3 (Kita et al., 1994).
The EGFR and c-erbB2 receptors when expressed at high
levels in NIH3T3 cells have transforming propertes, sugges-
ting that they may act as dominant oncogenes. Among the
four proteins, EGFR and c-erbB2 overxpression has been
extensively studied in a variety of tumours at the DNA,
mRNA and protein levels and where evaluated tends to be
associated with poor prognosis (Gullick, 1991; Lofts & Gul-
lick, 1991). Much less, however, is known about c-erbB3 and
c-erbB4.
The c-erbB3 receptor is epr d in normal human tissues,
with high levs present in mature, differentiated cells of the
gastrointestinal tract and in the neurons of the central ner-
vous system. It has been found to be overexpressed in breast
(Lemoine et al., 1992a), gastrointestinal (Poller et al., 1992;
Rajikumar et al., 1993; Sanidas et al., 1993) and pancreatic
cancers (Lemoine et al., 1992b), but so far no prognostic
significae has been demonstated. In order to study the
function of the c-erbB3 protein in normal and tumour cells
we have raised a monoclonal antibody against the extracel-
Jular domain of the protein. We describe here its production
and characterisation and its effects on the growth of breast
cancer cell lines expressng the c-erbB3 protein.
Maera ami 20 MIKi
Partialpurifeatin ofthe c-erbB3protein using wheat germ
lectin affinty chromatography
In initial attempts to raise monoclonal antibodies to the
extracellular domain of the c-erbB3 protein we immunised
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Balb/c mice with whole HER3 cells. These are derived from
the human kidney fibroblast cell line 293 by transfection with
a full-length c-erbB3 cDNA and express several million
molecules of c-erbB3 protein per cell. Although the mice
developed an immune response to the c-erbB3 protein as
determined by a capture enzyme-linked immunosorbent assay
(ELISA) technique (Rajkumar et al., 1994) no clones
secreting specific antibodies were obtained from several
fusions. The c-erbB3 protein was therefore parfially purified
from detergent lsates of HER3 cells using wheat germ lctin
Sepharose chromatography. This technique has been used
previously to purify the human EGF receptor (Woltjer et al.,
1992) and the c-erbB2 protein (N.L. Tuzi & WJ. Gullick,
unpublished results).
HER3 cells (human kidney fibroblasts transfected with the
HER3 cDNA) (a kind gift from Dr G. Plowman) grown to
confluence in a 175 cm2 flask were washed twice with
phosphate-buffered saline (PBS) containing 2mM ethylene
glycol bis-tetracetic acid (EGTA) and then 5 ml of ice-cold
lysis buffer (50mM Tris-HCL pH 7.4, containing 1% Triton
X-100, 5 mM EGTA, 150mM sodium chloride, 25mM ben-
7amidine, 2 mM phenylmethylsulphonyl fluoride and
I0jigml-' leupeptin) with I mgml-I bovine serum albumin
(BSA) (Sigma, Poole, UK) was added. The lysate was spun
at 3,000 r.p.m. for 10min at 4-C and the superatant
removed and placed on ice.
A 2 ml aliquot of wheat germ lectin Sepharose MB
(Sigma) was washed twice with lysis buffer (10 ml per wash).
The lysate was then added and tumbled for 1 h at 4C, and
spun at 2,000 r.p.m. for 2 min. The supernatant was colled
and placed on ice. The column was washed thrice with wash
buffer 1 (0.5 M sodium chloride and 0.1% Triton X-100) and
once with wash buffer 2 (50 mM HEPES, pH 7.4, 150mM
sodium chloride and 0.1% Triton X-100). A 900#il volume of
elution buffer [50mM HEPES, pH 7.4, 250mM N-
acetylucosamine (Sigma) and 0.1% Triton X-1001 was
added and tumbled at 4-C for 15 min. The tube was spun as
before and the eluate removed and stored and the process of
elution repeated once more. The eluate samples were pooled
together and concentrated using a Centricon 30 concentrator
(Amicon, Beverly, USA) and then the protein concentration
was estimated using the Bradford (1976) technique.
Immunisation withpartiallypurified c-erbB3protein
Balb/c mice were injected subcutaneously with 30-50Mg of
wheat germ purified c-erbB3 protein at 2 weekly intervals,
firstly with complete Freund's adjuvant and on the second
and third occasions with incomplete Freund's adjuvant. The
fourth dose was given a week after the third dose sub-
cutaneously, and this was followed 6 weeks later by the fifth
dose given without adjuvant, intraperitoneally. The mouse
used for the fusion was boosted 5 weeks after the fifth dose,
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with 100 gLg of the protein given intraperitoneally, and then
killed 4 days later.
Fusion and HATselection
Splenocytes were obtained from the immunised mouse and
fused with NSO myeloma cells at a ratio of 10:1, with
PEG1500 (Boehringer Mannheim, UK). The hybrids were
plated out into 22 96-well plates, which were already plated a
day earlier with feeder cells obtained from two unimmunised
Balb/c mice, in RPMI medium containing 15% fetal calf
serum (FCS) and 2 x OPI (oxaloacetate-pyruvate-insulin)
(Sigma), and HAT (hypoxanthine-aminopterin-thymidine)
selection was begun. On day 8, 100 IL of medium was
removed and 100 id of RPMI medium containing 15% FCS
and 1 x HAT was added to all the wells.
Screening ofthe hybrids
Three screens were set up to identify the specific hybrids:
1. an ELISA with FAST screening (Becton Dickinson,
Oxford, UK) to identify wells which had clones secreting
IgG antibodies;
2. ELISA with live HER3 and 293 cells;
3. immunoprecipitation of [5Simethionine metabolically
labelled cells expressing high levels of the c-erbB3 protein.
ELISA with FAST screening system Anti-mouse IgG Fc-
specific antibody (Pierce, Chester, UK) was diluted to
8pgm1-' in PBS, filter steilised and added to the troughs
provided in the screening kit. The beaded lids were placed in
the trough for 2 h at 37C and then transferred to another
trough containing filter-sterilised 2% BSA in PBS and
incubated for 1 h at 3rC. A lid was then placed in each of
the 96-well plates containing the hybrids followed by incuba-
tion for 2 h at 37C in a 5% carbon dioxide incubator.
Subsequently, the beaded lids were removed and washed with
PBS containing 0.05% Tween 20 and then incubated with
anti-mouse IgG (heavy and light chain specific) conjugated
with horseradish peroxidase (Pierce) at 1:6,000 dilution in
Superblock solution (Pierce) for 45 min at 3rC. The lids
were washed as above and then placed in a 96-well plate
containing 100gI per well of the substrate solution
(2 mgml1 o-phenylendiamine in sodium phosphate buffer,
pH 6, with 1 gl ml-' 30% hydrogen peroxide). The colour
which developed in the plates was then read using a Titertek
Multiscan plate reader.
ELISA with live cells HER3 cells and the parent 293 cells
were plated in alternate wells of a 96-well plate at 5 x 10'
cells per well in 1:1 DMEM-F12 medium containing 10%
FCS and allowed to grow until they were about 60%
confluent. The cells were washed with PBS-1% BSA and
then incubated with PBS-3% BSA-0.01% sodium azide for
1 h at 37C. The blocking agent was aspirated and then 50pi
of the hybridoma supematant was added to each pair of
wells followed by incubation for 40 min at 37C or for 2 h at
4 C. The superatants were aspirated and the plates were
washed twice with PBS-1% BSA-0.01% sodium azide and
then peroxidase-conjugated rabbit anti-mouse antibody at
1:500 dilution in PBS-1@/% BSA was added to all the wells
(50MO1 per well) followed by incubation for 30 min at 3rC.
The plates were then washed as before and the substrate
solution was added to each well. Following colour develop-
ment, the reaction was blocked with 4 N sulphuric acid and
then read at 480 nm.
Imnunoprecipitation Immunoprecipitation using [3Slmeth-
ionine-labelled HER3 cells was performed as described in
Rajkumar et al. (1993).
Isotyping and cloning
Using the Amersham mouse monoclonal isotyping kit
(Amersham, Aylesbury, UK) the isotype of the monoclonal
antibody was found to be IgGI kappa. The SGPI clone was
cloned twice using standard techniques.
Monoclonal antibodypurification
The SGP1 monoclonal antibody was purified using protein
A-Sepharose (Langone, 1982).
Western blotting
Proteins from HER3, 293, A431 and SKBR3 cell lysates were
electrophoretically transferred from a 7% SDS polyac-
rylamide gel to nitrocellulose (NC) (Gullick et al., 1986) and
probed using the SGPI monoclonal antibody. The blot was
developed using the ECL system (Amersham).
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections previously
known to be positive for c-erbB3 expression were used
(human kidney, submandibular salivary gland and colon) to
determine whether the SGPI monoclonal antibody could
recognise the denatured c-erbB3 protein. The procedure was
as described in Rajkumar et al. (1993).
Immunofluorescence
Immunofluorescent staining was performed as described by
Gullick et al. (1986). Briefly, paraformaldehyde-fixed HER3
or 293 cells grown on coverslips were washed with PBS and
the first antibody, 49.3 polyclonal antibody (Prigent et al.,
1992), SGPI monoclonal antibody and a negative control
IgGI antibody directed against Aspergillus niger glucose
oxidase (Dako, High Wycombe, UK) were added to each
pair of permeabilised and non-permeabiised cells at a dilu-
tion of 10Agml- in PBS-3@% BSA and incubated for 1 h at
37C. The cells were washed with PBS and then FITC-
conjugated anti-mouse or anti-rabbit antibody (Dako) at
1:25 dilution in PBS-0.5% BSA was added to the corres-
ponding wells and incubated for 30 min at 37C. The cells
were washed thoroughly with PBS and then mounted in
Hydromount (National Diagnostics, UK) and examined
under UV light and photographed.
Fluorescence-activated cell analysis
HER3, 293 and BT483 cells were trypsinised and washed
three times in ie-cold DMEM-2% FCS. Cell counts were
done on each cell suspension and I x 10' cells were then
incubated with lOzgmli' SGP1 monoclonal antibody
diluted in the same medium for 30 min at 4-C. An isotype-
matched negative control antibody (ICN) was added at
lOLgml-1 to two tubes containing BT483 and HER3 cells
and incubated as above. The cells were then washed three
times with DMEM-2% FCS and then incubated for 30 min
at 4-C with rabbit (Fab2) anti-mouse antibody conjugated to
FITC (Dako) that had been diluted 1:20 in the same
medium. The cells were washed three times in DMEM-2%
FCS, once with ice-cold PBS-2% FCS and once with ice-
cold PBS and analysed using a Coulter's Elite Profile H
FACScan.
Recognition ofthe non-N-glycosylatedform ofc-erbB3protein
HER3 cells were grown in six-well plates to about 75%
confluence, washed twice with PBS and then treated with
5pgml-' or 10ggmlPl tunicamycin (Sigma) for 45 min. The
cells were labelled with [5methionine for 2 h and then
immunoprecipitated with either SGPI monoclonal antibody
or 49.3 polyclonal antibody. Untreated HER3 cells were
labelled and immunoprecipitated with the same antibodies
and with the control antibody (Dako).
Effect on c-erbB3 kinase activity
HER3 and BT483 cells were trypsinised and plated at 3 x 105
cells per well in a 24-well plate in DMEM-0I% FCS andc-erbB3 STIMULATION 461
grown overnight. The cells were washed in PBS and then
50 ngml' NDF 2a (a generous gift from Dr Naili Liu,
Amgen) or 25pgml-' SGPI in DMEM was added to the
cells and incubated for 5 or 30mm respectively at 37C. As a
negative control, medium alone was added to cells and
incubated. The cells were washed twice in 1 ml of
PBS-2.5 mM EGTA, 10 mM sodium fluoride, 10 mM sodium
pyrophosphate and 1 mm sodium orthovanadate. The cells
were lysed in lysis buffer containg 10 mm sodium fluoride,
10mm sodium pyrophosphate, 1 mM sodium orthovanadate
and 1 mg ml-' BSA. The lysates were spun, the supermatant
removed and added to 10 id ofagarose-antiphosphotyrosine
antibody (Sigma) which had been washed once with
PBS-EGTA containing 10mM sodium fluoride, 10 mM
sodium pyrophosphate and 1 mM sodium orthovanadate.
The lysate and agarose-antibody complex were tumbled at
4-C for 2 h and then washed once with high-salt wash buffer
(PBS containing an additional 350mM sodium chloride and
0.2% Triton X-100) and twice with low-salt wash buffer (PBS
conta g 0.2% Triton X-100), both containing 10mM
sodium fluoride, 1OmM sodium pyrophosphate and 1 mM
sodium orthovanadate. After the final wash the supenatant
was removed as completely as possible and 20 id of 5 x sam-
ple buffer was added and heated at IOOC for 5 min. The
tubes were spun and the supermatant recovered and loaded
onto a 7% SDS-PAGE gel and then Western blotted with
49.3 polyclonal antibody and detet using the ECL system
(Amersham).
Effect on anchorage-independent growth
BT483, T47D and 293 cells were grown to 75% confluence
and then trypsinised and counted. The cells were resuspended
in DMEM-F12 medium at 1.2 x 10" cells ml-'. SGP1 and an
isotype-matched negative control antibody, both of which
had been filter sterilised, were diluted in serum-free medium
to lOOagml1'. Doubling dilutions of the antibodies were
prepared and 700#l of each concentration of antibody was
added to 300#d of each cell suspension, along with 200g1 of
FCS. The antibody-cell suspension was incubated for 90 min
at 37C.
A 0.5 ml aliquot of0.5% Noble apr was added as a base
layer to each well in a 24-well plate and allowed to set. A 1:3
dilution of 3% apr was mde in DMEM-F12 medium and
300jid of the agar-meium mixture was added to each tube
of cell suspension and mixed well. A 0.6ml volme of this
was then layered over the base layer and allowed to set.
Duplicate samples were done for each dilution of antibody
and cell hne. The plates were then plac in the incubator at
3rC. On day 8, 0.5 ml of the corresponding antibody was
added diluted in DMEM-F12 medium On day 16, colonies
more than 5gn in size were counted. The P-value was
calculated by chi-square test comparing the effect of SGPI
antibody and the control antibody versus no additions for
each of the cel lines.
The antibody recognised a protein of 160 kDa molcular
weight in the HER3 cell lines but not in the other cell lines.
The c-erbB3 protein in HER3 cells is expressed as a 160 kDa
molcular weight protein (Prigent et al., 1992; Plowman et
al., 1993b) but as a 180 kDa molcular weight protein in
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Fugwe 1 Immunoprcipitation of[`S)methionine-label]ed HER3
(lanes 1-3), A431 (lane 4), SKBR3 (lane 5), MDAMB453 (lane
6) and 293 (lane 7) cel lysate with whole SGP1 antibody (lanes
3-7), Fab fragment of SGPI (lane 2) and an isotype-matche
neative control antibody (lane 1).
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The c-erbB3 protein was partially purified and used to raise
monoclonal antibodies in a Balb/c mouse. A single clone was
obtained as descnrbed in the Materials and methods section.
Several xperIments were performed to detrmine the
specificity of the antibody. HER3 (Figure 1, lanes 1, 2 and
3), 293 (Figure 1, lane 7), A431 (Figure 1, lane 4), SKBR3
(Figure 1, lane 5) and MDAMB453 (Figure 1, lane 6) cells
(expressing high and low kvels ofc-erbB3, and high lehels of
EGF receptor, c-erbB2 and c-erbB4 proteins ectively)
were metaboically label and inmunoprecpitated with
puriied SGPI antibody (Figure 1, lanes 3-7), its Fab frig-
ment (Fligure 1, lane 2) and an isotype-matched control
antibody (Figure 1, lane 1). Specifically recognised proteins
were analysed by SDS-polyacrylamide gel electrophoresis
followed by autoradiography.
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Fugwe 2 Tunicamycin asay. Immunop tation of
[3S)neionmne-laeIed HER3 cell lysate with isotype-matched
negative control antibody (lane 1), polykonal 49.3 antibody
(lanes 2, 4 and 6) and SGP1 monoclonal antibody (lanes 3, 5 and
7). Lanes 1-3, no tunicamycin added; lanes 4 and 5, 5agml-'
tuicmrycin added; and lanes 6 and 7, lOgm -' tunicalycin
added.
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human breast tumour cell lines (Kraus et al., 1993; Rajkumar
et al., 1994) presumably as a result of differences in car-
bohydrate processng.
The SGP1 monoclonal antibody did not recognise c-erbB3
in Western blots ofcell lysates prepared from the HER3 cells
or in formalin-fixed, paraffin-embedded tissue sections
previously known to be positive for c-erbB3 protein (data not
shown). A protein of the correct size was, however, detected
by other antipeptide antibodies raised against three cytoplas-
mic domain synthetic peptides (Prigent et al., 1992),
indiating that SGP1 recognition is dependent on correct
folding of the c-erbB3 protein. In order to confirm that the
antibody recognised a protein determinant rather than a
post-translationally added carbohydrate chain, HER3 cells
were treated with two different concentrations, 5 jgml-'
(Figure 2, lanes 4 and 5) and lOagml-I (Figure 2, lanes 6
and 7), of the antibiotic tunicamycin, which prevents the
addition ofN-linked oligosaccharides to proteins. Cell lysates
were then immunoprecipitated with the monoclonal antibody
SGPI (Figure 2, lanes 3, 5 and 7), the polyclonal 49.3
antibody raised against a synthetic peptide from the cytoplas-
mic domain of the protein (Figure 2, lanes 2,4 and 6) and an
IgGl control antibody (Figure 2, lane 1). The polyclonal 49.3
antibody and the monoclonal SGP1 antibody detect both the
precursor (140 kDa) and the mature protein (160 kDa), sug-
gesting that the latter recogises the protein backbone of the
c-erbB3 protein.
Two types of experiment were done to confirm that the
SGPI antibody was directed to the extracellular domain of
the receptor and could bind to live cells. Intact and
detergent-permeabilised HER3 cells were treated with SGPI
or 49.3 antibodies and their reaction detected using appropri-
ate fluorescence-labelled second antibodies and UV micros-
copy. The polyclonal 49.3 antibody against a cytopLasmic
epitope gave a positive fluorescence reaction with the HER3
cels only when they were permeabiised (Figure 3b) and not
when they were non-permeabilised (Figure 3a), but the
monoclonal SGPI antibody gave a positive reaction in non-
permeabiised (Figure 3c) and permeabilised HER3 cells
(Figure 3d), suggesting that it reacts with the external
domain of the c-erbB3 protein. The negative control
antibody did not give any reaction under either conditions
(Figure 3e and f).
We next performed FACS analysis of a series of live cells
that express or lack expression of the c-erbB3 protein. The
FACS scan with live non-permeabilised 293 cells using the
monoclonal SGPI was essentially negative. The HER3 and
BT483 cells were positive with SGPI antibody but negative
with the control antibody. However, the BT483 cells appear
to have almost 100-fold kss c-erbB3 protein (Figure 4). Thus
the SGPI antibody recognised specifically a conformationally
dependent protein epitope of c-erbB3 and could bind to live
cells.
We were unable to demonstate any significant effect of the
monoclonal antibody on the anchorage-dependent growth of
the breast tumour cell lines. We next explored whether SGPI
could affect the anchorage-idependent growth of cells exp-
ressing the c-erbB3 protein. Three cell lines were selected for
study: BT483 and T47D are breast cancer-derived cell ines
that express a moderate amount of the c-erbB3 protein
(Lemoine et al., 1992a), while 293 cells (Prigent et al., 1992;
Rajkumar et al., 1994) lack expression. Anchorage-
independent growth of the BT483 cells (P= <0.01 at
25Mgml- and at 12.5 agml-') and T47D cells (P= <0.025
at 25pgmlI') (Figure 5a and b) was modestly increased by
SGP1 antibody at concentrations above 10 igmml'. The
negative control cell line, 293 cells, were found to be
unaffected by the SGP1 antibody at any of the antibody
concentrations used (data not shown). As a final test of
specificity, addition of the same range of concentrations of
the control isotype-matched antibody did not affect colony
growth (Figure 5a and b). These experments demonstrate
that the SGPI antibody had a weak but significnt agonistic
effect on the anchorage-dependent growth ofcell lnes expres-
Fwe 3 Immunofluorescne of erbilis and non-perneabilised HER3 cells a, c and e, Non-pernabilised. b, d and f,
Permeabilsed. a and b have been treated with polyclona 49.3 antibody, c and d have been treated with monocnal SGPI antibody
and e and f have been treated with isotype-matched negative control antibody.c-erbB3 STIMULATION 463
sing the c-erbB3 protein but did not affect the cloning
efficiency of 293 cells which lack the protein.
In the light of the effect on anchorageindependent growth,
we then attempted to demonstrate stimulation of the tyrosine
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kinase activity of the c-erbB3 protein in HER3 and BT483
cells by the monoclonal antibody SGP1. In the unstimulated
state the HER3 cells (Figure 6, lane 5) showed a 160 kDa
protein which increased in signal intensity 2- to 3-fold in the
presence of NDF (Figure 6, lane 1), indicating that NDF
does indeed stimulate c-erbB3 kinase activity. In the presence
of SGP1 antibody there is no obvious increase in the inten-
sity of the signal in the HER3 cells (Figure 6, lane 3). No
bands were vialised with the BT483 cells in the uns-
timulated state (Figure 6, lane 6) or in the presence of NDF
or SGPI (Figure 6, lanes 2 and 4).
Dio
We report here the production and characterisation of the
monoclonal antibody SGP1 raised against the c-erbB3 pro-
tein using wheat germ purified cell lysate from HER3 cells
that were enginred to overexpress the protein. This mono-
clonal antibody has been found to recognise the extracellular
domain of the receptor as evidenced by its positive
imunofluorescence reaction in non-permeabilised and
permeabilised cells and its positive reaction in FACS with
whole live cells. Treatment of the cells with tunicamycin,
which inhibits the addition of N-linked sugars to the EGF
receptor (Waterfield et al., 1982) and the c-erbB2 protein
(Harwerth et al., 1992), showed that the antibody recognises
a protein epitope of the c-erbB3 extracellular domain.
The effect on the anchorage-independent growth of BT483
and T47D cell lines is specific in that the control antibody at
any of the concentrations tested did not affect the cloning
efficiency of any of the cells, nor did SGP1 promote the
growth of 293 cells, which do not express the protein. The
Fge 4 FACS analysis. a, HER3 cells with control antibody. b,
HER3 cells with SGP1 antibody. c, BT483 cells with control
antibody. d, BT483 cells with SGPI antibody. MW
kDa
INV-
125-
AD 100-
c
0
75-
0
6 50-
z
25-
n-
I
,ly. I .
I A
11"
/I
/I
Z,
,,,
.,l
0 3.125 6.25 12.5 25
2 3 4 5 6
a
200-
97- 50 ' 1
50
Antibody concentration (gg ml-'1
125-
10o-
m U)
o 75-
0
o
°. 50-
6
z
25-
0-
b
o 3.125 6.;
:1-+
25 12.5 25
Antibody concentration (pg ml-"
Fwe 5 Histogram showing the effect of a control antibody
(L=) and the monoclonal SGPI antibody ( ) on the
anchorage-independent growth of BT483 a and T470 b cells. The
columns are mean of two samples; bars denote range and *
denotes a statistically significant difference.
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Fuwe 6 Effect of SGPI on c-erbB3 kinase activity. Lane 1,
HER3 cells stimulated with NDF; lane 2, BT483 stimulated with
NDF; lane 3, HER3 ells treated with SGP1 antibody; lane 4,
BT483 cells treated with SGP1 antibody; lane 5, HER3 cells
treated with medium alone; lane 6, BT483 cells treated with
medium alone.
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effect on anchorage-independent growth ofbreast tumour cell
lines could be due to an initial effect on cell viability or to an
effect on growth. The stimulation of anchorage-independent
growth does not occur at concentrations above 251gml-'
SGPI antibody. This could be because high concentrations of
antibody may lead to monovalent binding and not bivalent
binding, which is required for cross-linking two receptor
molecules so that they can dimerise and cross-phosphorylate
each other. This effect has previously been demonstrated with
platelet-derived growth factor (PDGF) receptor using either
high levels of ligand (Heldin et al., 1989) or antibodies to the
extracellular domain (Ronnstrand et al., 1988). This is
therefore supportive of c-erbB3 protein being activated by
SGPI antibody by a dimerisation mechanism.
We were unable to show a significant effect of the SGP1
antibody on the kinase activity of the c-erbB3 receptor,
although NDF clearly stimulates the kinae activity of c-
erbB3 protein in the HER3 cells. The effect has not been seen
in the breast tumour cell line BT483, presumably because of
the almost 100-fold lower levels of the receptors expressed as
demonstrated by FACS analysis.
Similar monoclonal antibodies have been raised against
EGFR and c-erbB2 receptors and have been found to be
either agonists or antagonists (Fernandez-Pol, 1985;
Harwerth et al., 1992;, 1993; Modjtahedi et al., 1993a, b).
These antibodies have been subsequently evaluated for
therapeutic effects either on their own or following conjuga-
tion to toxins, radionuclides or drugs. The c-erbB3 protein
has a distint expression in normal tissues of the gstrointes-
tinal tract, bladder and skin, being present at high levels in
the terminally differentiated cells of the mucosa and epider-
mis but absent or present only at very low levels in the
proliferating basal cells. The lack of expression in pro-
liferating cells or normal tissues and the overexpression in a
range of solid human tumour types (Lemoine et al., 1992a, b;
Poller et al., 1992; Rajkumar et al., 1993; Sanidas et al.,
1993) makes it a suitable target for antibody-directed enzyme
prodrug therapy (ADEPT). Studies using monoclonal
antibodies to EGFR and c-erbB2 have shown a synergistic
effect of combining the monoclonal antibody with
chemotherapeutic agents such as doxorubicin and cis-
platinum (Hancock et al., 1991; Baselga et al., 1993; Fan et
al., 1993). We therefore plan to evaluate the effect of the
monoclonal antibody SGP1 on tumour xenografts, on its
own, by conjugation to a prodrug system and by concurrent
administration of chemotherapeutic agents.
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